secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001559053-22-000030
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q2 2022 net loss $41.2M vs net income $27.6M a year ago; cash $510.1M
------------------------------------------------------------------------------

- Net loss of $41.2M ($0.88 loss per share) vs net income of $27.6M ($0.58 diluted EPS) in Q2 2021.
- Total revenue $1.3M from BMS collaboration, down from $60.1M in Q2 2021 which included Roche revenue.
- Cash and restricted cash $510.1M at June 30, 2022; no debt.
- FDA Fast Track granted for PRX012 (anti-Aβ antibody for Alzheimer's); topline Phase 1 data for PRX005 expected by year-end 2022.
- Full-year 2022 net cash used in operations and investing expected $120-$132M; year-end cash ~$454M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000030/0001559053-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000030/prta-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001559053-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer